Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical
The summary for the Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical: This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.
Federal Grant Title: | Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DK-19-028 |
Type of Funding: | Grant |
CFDA Numbers: | 93.847 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | November 3rd, 2020 |
Original Application Deadline: | November 3rd, 2020 |
Posted Date: | December 10th, 2019 |
Creation Date: | December 10th, 2019 |
Archive Date: | December 9th, 2020 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | December 10th, 2019 |
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. see the funding announcement for the eligibility details
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-028.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...
- • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...
- • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...
- • Diabetes Research Centers (P30 Clinical Trial Optional)
- • Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
- • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
- • Molecular Therapy Core Centers
- • Pilot and Feasibility Program in Human Islet Biology
- More Grants from the National Institutes of Health
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...